MY195395A - Fusion Immunomodulatory Proteins and Methods for Making Same - Google Patents

Fusion Immunomodulatory Proteins and Methods for Making Same

Info

Publication number
MY195395A
MY195395A MYPI2018002662A MYPI2018002662A MY195395A MY 195395 A MY195395 A MY 195395A MY PI2018002662 A MYPI2018002662 A MY PI2018002662A MY PI2018002662 A MYPI2018002662 A MY PI2018002662A MY 195395 A MY195395 A MY 195395A
Authority
MY
Malaysia
Prior art keywords
methods
making same
immunomodulatory proteins
egfr1
fusion
Prior art date
Application number
MYPI2018002662A
Inventor
Nagaraj Govindappa
Maria Melina Soares
Kedarnath Sastry
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Priority to MYPI2018002662A priority Critical patent/MY195395A/en
Publication of MY195395A publication Critical patent/MY195395A/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGF?RII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.
MYPI2018002662A 2014-03-10 2014-03-10 Fusion Immunomodulatory Proteins and Methods for Making Same MY195395A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MYPI2018002662A MY195395A (en) 2014-03-10 2014-03-10 Fusion Immunomodulatory Proteins and Methods for Making Same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2018002662A MY195395A (en) 2014-03-10 2014-03-10 Fusion Immunomodulatory Proteins and Methods for Making Same

Publications (1)

Publication Number Publication Date
MY195395A true MY195395A (en) 2023-01-18

Family

ID=87569433

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018002662A MY195395A (en) 2014-03-10 2014-03-10 Fusion Immunomodulatory Proteins and Methods for Making Same

Country Status (1)

Country Link
MY (1) MY195395A (en)

Similar Documents

Publication Publication Date Title
NZ711445A (en) Fusion immunomodulatory proteins and methods for making same
SA518400424B1 (en) Antibody molecules for cancer treatment
PH12019502283A1 (en) Anti-lag3 antibodies
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12018500950A1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
AU2017260389A1 (en) Chimeric neurotoxins
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2019003489A (en) Chimeric engulfment receptor molecules.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2016016886A (en) Anti-axl antibodies.
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
PH12016502220A1 (en) Means and methods for treating cmv
MY174248A (en) Targeted/immunomodulatory fusion proteins and methods for making same
MX2019013670A (en) Antibody and protein formulations.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MY181175A (en) Therapeutic hpv16 vaccines
MX2016002574A (en) Novel sez6 modulators and methods of use.
TW201613893A (en) Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
MX2016009590A (en) Apilimod compositions and methods for using same.
MX2018006249A (en) Novel anti-emr2 antibodies and methods of use.
MD20150109A2 (en) Mitochondrial proteins constructs and uses thereof
MX2018007817A (en) Novel anti-mmp16 antibodies and methods of use.
MX2015012281A (en) Improved tnf binding proteins.
MX2018007818A (en) Novel anti-upk1b antibodies and methods of use.
GEP20207081B (en) Process for producing iron (iii) casein n-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions